Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis.
GOS
Glasgow Coma Scale
TBI
cerebrolysin
functional outcome
mRS
modified Rankin Scale
traumatic brain injury
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
16
1
2019
Statut:
epublish
Résumé
Traumatic brain injury (TBI) remains a main public health problem being associated with high mortality and morbidity. The functional outcome of TBI remains unfavorable despite several surgical and medical therapies. Cerebrolysin is a neuropeptide with potential neuroregenerative entities. The aim of the current systematic review and meta-analysis was to investigate the effects of cerebrolysin on functional outcome in patients with moderate and severe TBI. Online databases used included Medline, Scopus, EMBASE, Google Scholar, Web of Science, and Cochrane Library. All the relevant studies with randomized clinical trial and cohort design evaluating the effects of intravenous cerebrolysin vs placebo on functional outcome of patients with TBI within the English literature up to October 2018 were included. The articles were reviewed by two independent authors and the data were extracted to a data sheet. Five articles (5,685 participants) were included in the current meta-analysis. The overall pooled findings using random-effects models among patients with TBI indicated that intravenous administration of cerebrolysin significantly increased Glasgow Outcome Scale score (SMD =0.30; 95% CI: 0.18 to 0.42; The results are mainly based on cohort studies and there is a lack of clinical trials in the literature. There is also heterogeneity among the studies regarding the dosage and duration of administration and the measurement of functional outcome. The results of the current study revealed that intravenous administration of cerebrolysin is associated with improved functional outcome in patients with TBI measured by the Glasgow Outcome Scale and the modified Rankin Scale scores.
Sections du résumé
BACKGROUND
BACKGROUND
Traumatic brain injury (TBI) remains a main public health problem being associated with high mortality and morbidity. The functional outcome of TBI remains unfavorable despite several surgical and medical therapies. Cerebrolysin is a neuropeptide with potential neuroregenerative entities.
OBJECTIVE
OBJECTIVE
The aim of the current systematic review and meta-analysis was to investigate the effects of cerebrolysin on functional outcome in patients with moderate and severe TBI.
DATA SOURCES
METHODS
Online databases used included Medline, Scopus, EMBASE, Google Scholar, Web of Science, and Cochrane Library.
STUDY ELIGIBILITY CRITERIA
METHODS
All the relevant studies with randomized clinical trial and cohort design evaluating the effects of intravenous cerebrolysin vs placebo on functional outcome of patients with TBI within the English literature up to October 2018 were included.
STUDY APPRAISAL AND SYNTHESIS METHODS
METHODS
The articles were reviewed by two independent authors and the data were extracted to a data sheet.
RESULTS
RESULTS
Five articles (5,685 participants) were included in the current meta-analysis. The overall pooled findings using random-effects models among patients with TBI indicated that intravenous administration of cerebrolysin significantly increased Glasgow Outcome Scale score (SMD =0.30; 95% CI: 0.18 to 0.42;
LIMITATIONS
CONCLUSIONS
The results are mainly based on cohort studies and there is a lack of clinical trials in the literature. There is also heterogeneity among the studies regarding the dosage and duration of administration and the measurement of functional outcome.
CONCLUSION
CONCLUSIONS
The results of the current study revealed that intravenous administration of cerebrolysin is associated with improved functional outcome in patients with TBI measured by the Glasgow Outcome Scale and the modified Rankin Scale scores.
Identifiants
pubmed: 30643411
doi: 10.2147/NDT.S186865
pii: ndt-15-127
pmc: PMC6311329
doi:
Types de publication
Journal Article
Langues
eng
Pagination
127-135Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Int Clin Psychopharmacol. 2003 Sep;18(5):271-8
pubmed: 12920387
JAMA. 2004 Jun 2;291(21):2531-2
pubmed: 15173131
Acta Neurochir Suppl. 2005;95:59-60
pubmed: 16463821
J Neural Transm (Vienna). 2008 May;115(5):683-92
pubmed: 18273537
J Med Life. 2009 Oct-Dec;2(4):350-60
pubmed: 20108748
Ann N Y Acad Sci. 2010 Jun;1199:125-37
pubmed: 20633118
Arch Phys Med Rehabil. 2010 Nov;91(11):1637-40
pubmed: 21044706
Drugs Today (Barc). 2012 Apr;48 Suppl A:3-24
pubmed: 22514792
Chin J Traumatol. 2012;15(5):279-83
pubmed: 23069098
Chin J Traumatol. 2013;16(2):84-8
pubmed: 23540895
J Neurosurg. 2013 Jun;118(6):1343-55
pubmed: 23581594
Br J Neurosurg. 2013 Dec;27(6):803-7
pubmed: 23656173
Stroke. 2013 Jul;44(7):1965-72
pubmed: 23696546
Public Health. 2013 Aug;127(8):704-9
pubmed: 23871394
Neurocrit Care. 2014 Aug;21(1):52-7
pubmed: 24408147
J Child Neurol. 2016 Jan;31(1):20-7
pubmed: 25123531
J Neurotrauma. 2015 Apr 15;32(8):571-80
pubmed: 25222349
Neuropsychiatr Dis Treat. 2014 Dec 03;10:2299-306
pubmed: 25516711
J Neurosurg. 2015 Apr;122(4):843-55
pubmed: 25614944
Dement Geriatr Cogn Disord. 2015;39(5-6):332-47
pubmed: 25832905
CNS Neurol Disord Drug Targets. 2015;14(5):587-99
pubmed: 25924999
Mol Neurobiol. 2015 Oct;52(2):899-912
pubmed: 26108180
J Clin Neurol. 2016 Jan;12(1):79-84
pubmed: 26365023
Life Sci. 2016 Jun 15;155:174-9
pubmed: 27210889
Neuropsychiatr Dis Treat. 2016 Jun 23;12:1517-23
pubmed: 27382294
Neurosurg Rev. 2018 Apr;41(2):427-438
pubmed: 27539610
Neurosurgery. 2017 Jan 1;80(1):6-15
pubmed: 27654000
Clin Neurol Neurosurg. 2017 Jan;152:34-38
pubmed: 27871029
World Neurosurg. 2017 May;101:130-136
pubmed: 28185976
MMWR Surveill Summ. 2017 Mar 17;66(9):1-16
pubmed: 28301451
J Clin Neurosci. 2017 Oct;44:143-147
pubmed: 28688622
Bull Emerg Trauma. 2017 Jul;5(3):190-196
pubmed: 28795064
Restor Neurol Neurosci. 2017;35(6):571-581
pubmed: 29172008
J Neurosurg. 2018 Nov 1;129(5):1295-1304
pubmed: 29303438
J Neurosurg. 2018 May 18;:1-8
pubmed: 29775144
Neuropsychiatr Dis Treat. 2018 Jun 14;14:1561-1567
pubmed: 29950840